ObjectiveTo investigate the effect of recombinant human pro-urokinase (rhPro-UK) on acute ST-segment elevation myocardial infarction percutaneous coronary intervention (PCI) in treating myocardial perfusion and the incidence of major adver cardiovascular events (MACE). MethodsThe clinical data of 68 patients with acute ST-segment elevation myocardial infarction admitted to our hospital from July 2018 to July 2020 were retrospectively analyzed, among which 34 patients treated with simple PCI were included in the control group, and other 34 patients treated with rhPro-UK combined with PCI were enrolled in the observation group. The general conditions were compared between the two groups; moreover, myocardial perfusion condition and the incidence of MACE were also compared between the two groups. ResultsThere were no statistically significant differences in general conditions between the two groups, as for gender, age and body mass index (P＞0.05). After surgery, the observation group yielded a higher effective myocardial perfusion rate, and a superior condition of myocardial perfusion as compared with the control group, with statistically significant differences (P＜0.05). There was no statistically significant difference in the incidence of MACE after surgery between the two groups (P＞0.05). ConclusionrhPro-UK combined with PCI can effectively improve the myocardial perfusion rate of patients with acute ST-segment elevation myocardial infarction, but it does not increase the risk of postoperative adverse events.

无